| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/BJU.13739 |
| P8608 | Fatcat ID | release_usp2jesrbne2llqe6i3m4jitsa |
| P698 | PubMed publication ID | 27981732 |
| P2093 | author name string | Fouad Aoun | |
| Patrick Flamen | |||
| Thierry Gil | |||
| Alexandre Peltier | |||
| Ksenija Limani | |||
| Roland van Velthoven | |||
| Spyridon Sideris | |||
| Simone Albisinni | |||
| Nicolas Sirtaine | |||
| Carlos Artigas | |||
| Ibrahim Biaou | |||
| Eric Hawaux | |||
| Francois-Xavier Otte | |||
| Julien Grosman | |||
| P2860 | cites work | Cancer statistics, 2016 | Q29547383 |
| Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference | Q34541651 | ||
| The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer | Q35043569 | ||
| Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. | Q35874782 | ||
| PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer | Q36109230 | ||
| Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer | Q36854835 | ||
| Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study | Q36942136 | ||
| Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database group | Q37173930 | ||
| A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence | Q37641490 | ||
| Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis. | Q38169092 | ||
| EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. | Q38169849 | ||
| Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature | Q38252871 | ||
| Next revolution in molecular theranostics: personalized medicine for urologic cancers. | Q38559336 | ||
| Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy | Q38853977 | ||
| Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists | Q38941339 | ||
| Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer | Q39690658 | ||
| Prostate cancer nodal oligometastasis accurately assessed using prostate-specific membrane antigen positron emission tomography-computed tomography and confirmed histologically following robotic-assisted lymph node dissection | Q40434230 | ||
| Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer | Q41038146 | ||
| Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score | Q47965751 | ||
| (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. | Q48278153 | ||
| 68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer. | Q50556005 | ||
| Clinical Impact of 68Ga-PSMA PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer. | Q51713748 | ||
| (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer. | Q52985772 | ||
| Paget bone disease demonstrated on (68)Ga-PSMA ligand PET/CT. | Q52989823 | ||
| (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? | Q53505313 | ||
| Prostate Specific Membrane Antigen Positron Emission Tomography May Improve the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer. | Q54460691 | ||
| Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT | Q57661498 | ||
| P433 | issue | 2 | |
| P921 | main subject | tomography | Q841267 |
| P304 | page(s) | 197-203 | |
| P577 | publication date | 2016-12-15 | |
| P1433 | published in | BJU International | Q4835773 |
| P1476 | title | Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary ana | |
| P478 | volume | 120 |
| Q42371612 | 177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer |
| Q50083626 | 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. |
| Q47269407 | 68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends |
| Q48568705 | Actual impact of 68Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence |
| Q90383126 | Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging |
| Q48089415 | Clinical impact of PSMA-based 18F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. |
| Q59137133 | Clinical implications of PET/CT in prostate cancer management |
| Q47241139 | Current status of theranostics in prostate cancer. |
| Q99623448 | Evaluation of the clinical use of PET/CT with 68Ga-PSMA for the assessment of biochemical recurrence of low or intermediate-risk prostate cancer |
| Q56379286 | Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy |
| Q57802680 | Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy |
| Q90087024 | Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer |
| Q89823517 | Imaging for Metastasis in Prostate Cancer: A Review of the Literature |
| Q90523257 | Impact of 68Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis |
| Q64299358 | Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy |
| Q56383213 | Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row |
| Q55118858 | Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. |
| Q61814881 | Pelvic salvage (SBRT) radiotherapy based on Ga-PSMA PET/CT: About a case |
| Q92722967 | Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and its Role in Salvage Lymph Node Dissection |
| Q60918373 | Randomized prospective phase III trial of Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT] |
| Q50034009 | Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer |
| Q50186825 | The Utility of PET/CT in External Radiation Therapy Planning of Prostate Cancer. |
| Q49833204 | The role of PSMA PET scans in salvage therapy planning |
| Q57111933 | Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen |
Search more.